Metagenomi finds novel gene-editing tools by mining microbial samples from around the world. Already partnered with Moderna and Ionis Pharmaceuticals, the company said its IPO cash will support ongoing preclinical research.
Metagenomics offers advances for infectious disease diagnostics by providing the diagnostic technology to detect a potentially unlimited numbers of known and novel microbes from a single sample in one test.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
CosmosID's powerful diagnostic platform can identify some 20,000 microbes, based on an intricate understanding of microbial biomarkers.